ACI-35.030, an experimental anti-tau vaccine that AC Immune is developing for Alzheimer’s disease, was able to potently induce…
Articles by Marisa Wexler, MS
Acadia Pharmaceuticals has resubmitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of Nuplazid…
A recent proposal to limit Medicare coverage for Aduhelm (aducanumab) and similar medicines to Alzheimer’s disease patients who are enrolled…
An optimized version of ACI-24, an experimental vaccine designed to induce an immune response against abnormal protein clumps that drive…
A recent proposal that Medicare only cover Aduhelm (aducanumab) for patients with Alzheimer’s disease who are enrolled in…
The U.S. Food and Drug Administration (FDA) has placed a full clinical hold on COR388 (atuzaginstat), an investigational oral therapy…
3K3A-APC, an investigational therapy for stroke about to enter Phase 3 clinical testing, may also help to protect the brain…
The U.S. Food and Drug Administration (FDA) has put a clinical hold Denali Therapeutics’ application to begin clinical testing…
A new proposal in the U.S. that Medicare cover the cost of Aduhelm (aducanumab) only for people enrolled in…
Alzheimer’s News Today brought you coverage of the latest scientific advances, developments in treatment, and clinical trials related to …